V.3 Summary of risk minimisation measures

Not applicable

Part VI: Summary of the risk management plan

Summary of risk management plan for Paklitaxel albumin Reddy (Paclitaxel albumin)

This is a summary of the risk management plan (RMP) for Paklitaxel albumin Reddy. The RMP details important risks of Paklitaxel albumin Reddy, how these risks can be minimised, and how more information will be obtained about Paklitaxel albumin Reddy's risks and uncertainties (missing information).

Paklitaxel albumin Reddy's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Paklitaxel albumin Reddy should be used.

Important new concerns or changes to the current ones will be included in updates of Paklitaxel albumin Reddy's RMP.

I. The medicine and what it is used for

Paklitaxel albumin Reddy monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated.

Paklitaxel albumin Reddy in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.

Paklitaxel albumin Reddy in combination with carboplatin is indicated for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy (see SmPC for the full indication). It contains paclitaxel albumin as the active substance and it is given by intravenous route.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Paklitaxel albumin Reddy, together with measures to minimise such risks and the proposed studies for learning more about Paklitaxel albumin Reddy's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine’s packaging;
- The authorised pack size - the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine’s legal status - the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including Periodic Safety Update Report (PSUR) assessment so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

II.A List of important risks and missing information

Important risks of Paklitaxel albumin Reddy are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Paklitaxel albumin Reddy. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

List of important risks and missing information	
Important identified risks	• None
Important potential risks	• None
Missing information	• None

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Paklitaxel albumin Reddy.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Paklitaxel albumin Reddy.